Introduction {#Sec1}
============

Patients with smoke inhalation are at a high risk of death or major morbidities. Cyanide is a documented cause for rapid death after intoxication from smoke \[[@CR1]\]. Several cyanide antidotes have been proposed (i.e., sodium nitrite, amyl nitrite, sodium thiosulfate, 4-dimethylaminophenol, dicobalt edetate, and hydroxocobalamin) with utilization varying across countries \[[@CR2]\]. Several experts suggested using hydroxocobalamin as the first-line treatment after suspected cyanide intoxication due to its perceived good safety profile \[[@CR3]\]. However, other experts raised concerns about liberalizing the use of hydroxocobalamin after smoke inhalation due to a lack of data on both efficacy and tolerance. They have called for additional investigations \[[@CR4], [@CR5]\].

Recently, nephrotoxicity of hydroxocobalamin due to oxalate nephropathy was reported in a single-center study among burn patients \[[@CR4]\]. The objective of this cohort study was to assess the association between the use of hydroxocobalamin and the risk of acute kidney injury (AKI) and death in intensive care unit (ICU) patients with smoke inhalation.

Methods {#Sec2}
=======

Study population and settings {#Sec3}
-----------------------------

We conducted a retrospective, multicenter study in 21 ICUs in France. All consecutive adult (≥ 18 years old) patients admitted between January 2011 and December 2017 with the final diagnosis of smoke inhalation were included in this study. Patients discharged alive at home within 24 h from admission (reflecting absence of severity) were excluded. Patient files were retrieved using our national coding for smoke inhalation injury (code CIM T599 for all patients and associated: X00·0, X 09·0, X09·9, X47·0, X47·08, X47·9, X67·0, X67·9, T58) (Additional file [1](#MOESM1){ref-type="media"}: Table S1). This academic investigator-driven study was registered at [ClinicalTrials.gov](http://clinicaltrials.gov), NCT03558646. The study protocol was approved by our local research ethical committee (Comité de Protection des Personnes 2013/17NICB). The use of patient's data was allowed in cases of death and/or when proxies could not be contacted.

Primary outcome {#Sec4}
---------------

The primary outcome was AKI. AKI was defined according to Kidney Disease Improving Global Outcome (KDIGO) within 7 days following admission using the serum creatinine criteria \[[@CR6]\].

Secondary outcome {#Sec5}
-----------------

Secondary outcomes were severe AKI (severe AKI defined patients by AKI stage 2 or 3), major associated kidney events (MAKE) in the ICU, which includes death and/or renal replacement therapy (RRT), and/or persistent AKI at ICU discharge. Persistent AKI was defined as an elevated SCreat level from baseline by \> 1.5-fold or \> 0.3 mg/dL (26.3 μmol/L) at ICU discharge or RRT at ICU discharge and survival in the ICU.

Data collections and definitions {#Sec6}
--------------------------------

Data were collected through a standardized case report form. Each form was manually encoded in each participating center using the initials and year of birth of the patient. Admission serum creatinine (SCreat) was used for baseline SCreat. Severe burn was defined as total body surface area (TBSA) burn ≥ 20% and/or deep TBSA burn ≥ 10% with organ support on admission (i.e., mechanical ventilation or need for vasopressors) \[[@CR7]\]. When a fiber-optic bronchoscopy was performed, inhalation injury was classified according to fiber-optic bronchoscopy inhalation injury classification \[[@CR8]\].

Sample size and statistical analysis {#Sec7}
------------------------------------

Due to the exploratory design of this study, no sample size could be calculated. Categorical variables were presented using percentages and counts, and continuous variables were presented using means and standard deviations or medians with the 25th and 75th percentiles. Categorical variables were compared using the chi-square test or Fisher's exact test as appropriate. Continuous variables were compared using the Student *t* test or the Mann--Whitney *U* test as appropriate.

Actuarial mortality was plotted using the Kaplan--Meier estimator. Administrative censoring was applied at day 90. The impact of hydroxocobalamin administration on AKI was estimated using a multivariate logistic regression model adjusting age, comorbidities, aminoglycoside, vancomycin and iodine contrast agent utilization during hospitalization, peak value of creatinine phosphokinase, prehospital cardiac arrest, prehospital minimal GCS, severe burn, initial sequential organ failure assessment (SOFA) score without the renal item, lactate at admission, need for catecholamine infusion at admission, the SAPS2 score calculated over the first 24 h, the interaction between hydroxocobalamin administration and prehospital cardiac arrest, and the center. The impact of hydroxocobalamin administration on secondary outcomes (severe AKI, MAKE, survival) was estimated using a multivariate logistic regression model adjusting for the same confounders. An interaction term between prehospital cardiac arrest and hydroxocobalamin was also introduced in the model. Odds ratios were provided together with their 95% confidence intervals.

Missing data were handled using multivariate imputation by chained equations (mice package for R, 50 imputations) \[[@CR9]\].

Because plasma lactate level was shown to correlate with cyanide, we performed subgroup analysis in patients with plasma lactate level at admission above median of the entire cohort and above 8 mmol/L \[[@CR10], [@CR11]\]. A subgroup analysis was also performed in patients with severe burns.

Results {#Sec8}
=======

Among 854 patients with smoke inhalation, 739 were included in the analysis after exclusion of patients discharged at home within 24 h. Three hundred eighty-six (55.2%) patients received hydroxocobalamin. Patient's characteristics and comparison between patients who received hydroxocobalamin and those who did not are presented in Table [1](#Tab1){ref-type="table"}. The number of patients per center is summarized in Additional file [2](#MOESM2){ref-type="media"}: Table S2. Table 1Comparison between patients with or without hydroxocobalaminCharacteristicsAll patients, *N* = 739Hydroxocobalamin, *N* = 386No hydroxocobalamin, *N* = 353*p*At admission - Age in years50 (36--63)50 (38--62)48 (33--64)0.4858 - Sex female, n (%)271 (36.7)140 (36.3)131 (37.1)0.9335 - BMI in kg/m^2^25 (22--28)24 (22--28)25 (22--28)0.2416 - Prehospital cardiac arrest (%)46 (6.2)42 (10.9)4 (1.1)\< 0.0001 - Prehospital GSC /1515 (9--15)13 (5--15)15 (14--15)\< 0.0001Comorbidities - CKD, *n* (%)6 (0.8)6 (1.6)0 (0)0.0315 - CHT, *n* (%)141 (19.1)71 (18.4)70 (19.9)0.6872 - Diabetes mellitus, *n* (%)54 (7.3)33 (8.5)21 (6)0.2243 - Peripheral artery disease, *n* (%)22 (3)9 (2.3)13 (3.7)0.3882 - CHF, *n* (%)33 (4.5)20 (5.2)13 (3.7)0.4197Burn characteristic - Burn, *n* (%)577 (78.1)286 (74.1)291 (82.4)0.0081 - TBSA %20 (3--47)15 (0--45)24 (6--50)0.0163 - Deep burn TBSA %9 (0--30)5 (0--30)10 (0--32)0.1985SOFA at admission4 (1--7)5 (2--8)2 (0--5)\< 0.0001MAP in mmHg86 (72--101)86 (68--101)86 (73--101)0.4383Vasopressors, *n* (%)226 (30.6)153 (39.6)73 (20.7)\< 0.0001HbCO %3.6 (1.9--9.7)7 (3--15)3 (2--5)\< 0.0001Biological data - Plasma lactate in mmol/L3.0 (1.8--5.2)3.5 (2.1--6)2.6 (1.4--4.1)\< 0.0001 - Serum creatinine at admission in μmol/L76 (59--101)82 (63--106)71 (56--93)0.0031 - Maximal serum creatinine in μmol/L100 (73--162)108 (77--182)90 (71--137)0.0027Inhalation fibroscopic status, *n* (%)305 (41.3)105 (27.5)200 (56.7)\< 0.0001 - Grade 0, *n*1 (0.1)0 (0)1 (0.3)1 - Grade 1, *n*121 (16.4)31 (8)90 (25.5)\< 0.0001 - Grade 2, *n*110 (14.9)37 (9.6)73 (20.7)\< 0.0001 - Grade 3, *n*73 (9.9)37 (9.6)36 (10.2)0.8764During ICU hospitalization - In-ICU mortality, *n* (%)243 (32.9)147 (38.1)96 (27.2)0.0022 - AKI in the first week, *n* (%)288 (39)166 (43)122 (34.6)0.0229 - Stage of AKI  - Stage 1, *n* (%)102 (13.8)52 (13.5)50 (14.2)0.8682  - Stage 2, *n* (%)39 (5.3)22 (5.7)17 (4.8)0.7099  - Stage 3, *n* (%)147 (19.9)92 (23.8)55 (15.6)0.0066  - Severe AKI, *n* (%)186 (25.2)114 (29.5)72 (20.4)0.0055 RRT at day 7, *n* (%)136 (18.8)86 (22.3)50 (14.2)0.006 - RRT in ICU, *n* (%)183 (24.8)107 (27.7)76 (21.5)0.0626 - MAKE, *n* (%)313 (42.4)187 (48.4)126 (35.7)0.0006 - Shock in ICU, *n* (%)402 (54.4)225 (58.3)176 (50)0.0261 - Length of stay in ICU in days15 (3--44)11 (2--36)22 (3--50)0.0161 - SAPS242 (27--60)49 (31--77)37 (23--54)\< 0.0001 - In-ICU survival, *n* (%)496 (67.1)239 (61.9)257 (72.8)0.0022Nephrotoxic in ICU - Aminoglycoside during hospitalization188 (25.4)81 (21)107 (30.3)0.0047 - Glycopeptide during hospitalization41 (5.5)16 (4.1)25 (7.1)0.1138 - Contrast agent74 (10)48 (12.4)26 (7.4)0.0299All data are expressed as median ± 25--75 interquartile or percentage (%)*BMI* body mass index, *GCS* Glasgow coma scale, *CKD* chronic kidney disease, *CHT* chronic hypertension, *CHF* chronic heart failure, *TBSA* total body surface area, *SOFA* sequential organ failure assessment, *MAP* mean arterial pressure, *HbCO* carboxy hemoglobin, *ICU* intensive care unit, *AKI* acute kidney injury, *Severe AKI* AKI stage 2 and 3, *RRT* renal replacement therapy, *MAKE* major associated kidney events, *Shock in ICU* catecholamine need during ICU stay, *SAPS2* simplified acute physiology score 2

Acute kidney injury {#Sec9}
-------------------

Two hundred eighty-eight (39%) patients developed AKI in the first week, including 186 (25.2%) patients with severe AKI. In univariate analysis, the use of hydroxocobalamin was associated with AKI, severe AKI, and RRT (Table [1](#Tab1){ref-type="table"}). After adjusting for potential confounders, hydroxocobalamin remained associated with AKI and severe AKI and RRT (Table [2](#Tab2){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"} and Additional file [3](#MOESM3){ref-type="media"}: Table S3). Severe burns, aminoglycoside administration, admission plasma lactate level, chronic hypertension, and SAPS2 were also associated with AKI (Table [2](#Tab2){ref-type="table"}). Table 2Multivariate analyses of factors associated with AKI and severe AKIVariableAdjusted odds ratioLCIUCI*p*AKI Hydroxocobalamin1.5971.0552.4190.027 Severe burn2.911.8414.601\< 0.001 SOFA score without renal item1.0030.8911.1290.963 Prehospital GCS1.0640.9971.1360.063 Aminoglycoside during hospitalization2.9031.1844.473\< 0.001 Glycopeptide during hospitalization1.7310.7733.8770.182 Admission plasma lactate1.1051.0341.1820.003 Age1.0090.9971.0210.154 Peripheral arterial obstructive disease0.9130.3082.7130.87 Diabetes mellitus1.4870.7263.0460.278 Chronic hypertension2.1341.2483.6490.006 CKD0.9470.1197.5040.959 Prehospital cardiac arrest0.4180.0257.0960.546 Vasopressor at admission1.7780.933.3960.081 Maximum CPK1.0810.9971.2420.269 Contrast agent1.4450.8032.6010.219 SAPS21.0211.0061.0360.009 Center1.0140.9761.0530.484 Interaction between prehospital cardiac arrest and hydroxocobalamin2.2450.12540.3670.583Severe AKI Hydroxocobalamin1.7721.1372.7620.012 Age1.0060.9931.0190.394 Peripheral arterial obstructive disease0.5520.1831.6680.292 Diabetes mellitus1.2010.5822.4790.619 Chronic hypertension2.0451.1683.5790.012 Prehospital cardiac arrest0.7750.04314.120.863 Severe burn2.1571.2763.6450.004 SOFA score at admission without renal item1.0470.9241.1850.471 CKD2.4070.28520.2990.418 Vasopressor at admission1.2980.6532.5790.456 Prehospital GCS1.040.9731.110.248 Admission plasma lactate1.1511.0621.2480.001 Maximum CPK1.0990.9041.3370.324 Aminoglycoside during hospitalization2.4181.5393.801\< 0.001 Contrast agent0.8890.4761.6630.713 Glycopeptide during hospitalization2.8731.3186.2610.008 SAPS21.021.0061.0350.006 Center1.0420.9981.0890.061 Interaction between prehospital cardiac arrest and hydroxocobalamin0.4120.028.3310.563*AKI* acute kidney injury, *LCI* lower confidence interval, *UCI* upper confidence interval, *p p* value, *SOFA score* sequential organ failure assessment, *GCS* Glasgow coma scale, *CKD* chronic kidney disease, *CPK* creatinine phosphokinase, *SAPS2* simplified acute physiology score 2 Fig. 1Non-adjusted and adjusted odds ratio (lower confidence interval, upper confidence interval) of hydroxocobalamin for AKI (upper panel) and severe AKI (lower panel). Adjusted on the following variables: age, peripheral arterial obstructive disease, diabetes mellitus, chronic hypertension, chronic kidney disease, prehospital cardiac arrest, severe burn, SOFA score without kidney item, vasopressors at admission, prehospital Glasgow coma scale, plasmatic lactate level at admission, maximum creatinine phosphokinase plasmatic level, contrast agent, use of vancomycin and aminoglycosides, and simplified acute physiology score 2

Three hundred and thirteen (42.4%) patients met the criteria for MAKE during ICU stay. Hydroxocobalamin was not associated with the risk of MAKE in multivariate analysis (OR = 0.784, LCI = 0.456, UCI = 1.349, *p* = 0.379). Factors associated with MAKE in ICU are summarized in Additional file [4](#MOESM4){ref-type="media"}: Table S4.

ICU mortality {#Sec10}
-------------

Mortality in ICU was 32.9% (*N* = 243). Patients who received hydroxocobalamin had higher severity scores and higher mortality rate. Factors associated with mortality in univariate analysis are summarized in Table [3](#Tab3){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. In multivariate analysis, hydroxocobalamin was not associated with survival (OR = 1.114, LCI = 0.691, UCI = 1.797, *p* = 0.657). Age, severe burns, SAPS2, plasma lactate level at admission, and the center were associated with mortality in ICU (Table [4](#Tab4){ref-type="table"}). Three hundred and ninety-two patients (53%) had admission plasma lactate level above the median (median = 3.0 \[1.8--5.2\] mmol/L), and 74 patients had admission plasma lactate level ≥ 8 mmol/L (median = 10.5 \[8.9--12.8\] mmol/L) (among 681 (92.2%) patients with plasma lactate available at admission, Additional file [5](#MOESM5){ref-type="media"}: Table S5). No association between hydroxocobalamin use and survival was observed after adjustment for confounding factors in the subgroups of patients with admission plasma lactate level above the median (OR = 0.76; LCI = 0.398, UCI = 1.451, *p* = 0.403) or in the group of patients with admission plasma lactate level ≥ 8 mmol/L (OR = 2.604, LCI = 0.361, UCI = 18.79, *p* = 0.336). In multivariate analysis, hydroxocobalamin was neither associated with survival (OR = 0.85, LCI = 0.5, UCI = 1.447, *p* = 0.549) among 405 (54.8%) patients with severe burns (Additional file [6](#MOESM6){ref-type="media"}: Table S6). Table 3Patient characteristicsCharacteristicsAll patients, *N* = 739Survivors, *N* = 496Non-survivors, *N* = 243*p*At admission - Age in years50 (36--63)46 (33--59)56 (43--72)\< 0.0001 - Sex female, *n* (%)271 (36.7)180 (36.3)91 (37.4)0.8214 - BMI in kg/m^2^25 (22--28)24 (22--28)25 (22--29)0.0822 - Prehospital cardiac arrest (%)46 (6.2)11 (2.2)35 (14.4)\< 0.0001 - Prehospital GSC /1515 (9--15)15 (13--15)14 (3--15)\< 0.0001Comorbidities - CKD, *n* (%)6 (0.8)2 (0.4)4 (1.6)0.0948 - Hypertension, *n* (%)141 (19.1)81 (16.3)60 (24.7)0.0088 - Diabetes mellitus, *n* (%)54 (7.3)28 (5.6)26 (10.7)0.0198 - CAOD, *n* (%)22 (3)7 (1.4)15 (6.2)0.0008 - CHF, *n* (%)33 (4.5)20 (4)13 (5.3)0.4858Burn characteristic - Burn, *n* (%)577 (78.1)357 (72)220 (90.5)\< 0.0001 - TBSA %20 (3--47)12 (0--30)50 (20--73)\< 0.0001 - 3rd degree TBSA %9 (0--30)2 (0--15)33 (10--58)\< 0.0001SOFA at admission4 (1--7)2 (1--5)7 (3--10)\< 0.0001MAP in mmHg86 (72--101)89 (76--102)80 (62--97)\< 0.0001Vasopressor, *n* (%)226 (30.6)90 (18.1)136 (56)\< 0.0001Hydroxocobalamin, *n* (%)386 (52.2)239 (48.2)147 (60.5)0.0021HbCO %4 (2--10)4 (2--11)3 (2--7)0.0323Biological data - Plasmatic lactate in mmol/L3.0 (1.8--5.2)2.5 (1.4--3.8)4.8 (3--7.6)\< 0.0001 - Serum creatinine in μmol/L76 (59--101)71 (56--88)100 (72--123)\< 0.0001 - Maximal serum creatinine in μmol/L100 (73--162)84 (68--113)137 (102--212)\< 0.0001Inhalation fibroscopic status (%)305 (41.3)175 (35.3)130 (53.5)\< 0.0001 - Grade 0, *n*1 (0.1)1 (0.2)0 (0)1 - Grade 1, *n*121 (16.4)90 (18.2)31 (12.8)0.0795 - Grade 2, *n*110 (14.9)67 (13.5)43 (17.7)0.1638 - Grade 3, *n*73 (9.9)17 (3.4)56 (23.1)\< 0.0001 - During ICU hospitalization - AKI in the first week, *n* (%)288 (39)126 (25.4)162 (66.7)\< 0.0001  - Stage of AKI day 7  - Stage 1, *n* (%)102 (13.8)63 (12.7)39 (16)0.2601  - Stage 2, *n* (%)39 (5.3)16 (3.2)23 (9.5)0.0007  - Stage 3, *n* (%)147 (19.9)47 (9.5)100 (41.2)\< 0.0001  - Severe AKI186 (25.2)63 (12.7)123 (50.6)\< 0.0001 - RRT at day 7, *n* (%)136 (18.8)44 (8.9)92 (37.9)\< 0.0001 - RRT in ICU, *n* (%)183 (24.8)58 (11.7)125 (51.4)\< 0.0001 - MAKE, *n* (%)313 (42.4)69 (13.9)243 (100)\< 0.0001 - Shock in ICU, *n* (%)402 (54.4)191 (38.5)211 (86.8)\< 0.0001 - Length of stay in ICU15 (3--44)25 (4--50)6 (1--24)0.0001 - SAPS242 (27--60)32 (22--46)61 (46--75)\< 0.0001Nephrotoxic in ICU - Aminoglycoside188 (25.4)115 (23.2)73 (42.9)0.0548 - Vancomycin41 (5.5)22 (4.4)19 (7.8)0.4011 - Contrast product74 (10)41 (8.3)33 (13.6)0.0331All data are expressed as median ± 25--75 interquartile or percentage (%)*BMI* body mass index, *GCS* Glasgow coma scale, *CKD* chronic kidney disease, *CAOD* chronic arterial occlusive disease, *CHF* chronic heart failure, *TBSA* total body surface area, *SOFA* sequential organ failure assessment, *MAP* mean arterial pressure, *HbCO* carboxy hemoglobin, *ICU* intensive care unit, *AKI* acute kidney injury, *RRT* renal replacement therapy, *MAKE* major associated kidney events, *SAPS2* simplified acute physiology score 2 Fig. 2Unadjusted Kaplan--Meier curve of survival incidence during the 90 days following admission between patients who received hydroxocobalamin and those who did not Table 4Multivariate analyses of factors associated with ICU mortalityICU mortalityVariableAdjusted odds ratioLCIUCI*p*Hydroxocobalamin1.1140.6911.7970.657Age1.0371.0231.05\<  0.001Prehospital cardiac arrest1.0910.0717.1260.95Severe burn4.7922.6658.617\<  0.001SOFA score at admission1.0740.9421.2250.283Admission plasma lactate1.2561.1541.366\<  0.001Vasopressors at admission1.5710.7373.3460.241Prehospital GCS1.0330.9611.110.383SAPS21.0391.021.059\<  0.001Center1.0841.0331.1370.001Interaction between prehospital cardiac arrest and hydroxocobalamin6.3270.354112.9930.209*ICU* intensive care unit, *LCI* lower confidence interval, *UCI* upper confidence interval, *p p* value, *SOFA score* sequential organ failure assessment score, *GCS* Glasgow coma scale, *SAPS2* simplified acute physiology score 2

Discussion {#Sec11}
==========

In this retrospective, multicenter study, we observed a higher risk of AKI and severe AKI associated with administration of hydroxocobalamin after adjustment for potential confounding factors. Hydroxocobalamin was not associated with improved survival.

Cyanide poisoning has been suspected to account for deaths after smoke inhalation \[[@CR12]\]. Hydroxocobalamin (Cyanokit®, Merck Santé SAS) is approved by the Food and Drug Administration for the treatment of cyanide poisoning. Hydroxocobalamin chelates cyanide to form cyanocobalamin, which is excreted by the kidneys. Experts have advocated the use of cyanide antidotes after smoke inhalation with suspected cyanide intoxication. While preclinical data have suggested improved hemodynamics with hydroxocobalamin in animal models of cyanide intoxication, clinical data are very limited. In two retrospective studies, Borron et al. and Fortin et al. described the outcome of patients receiving hydroxocobalamin after smoke inhalation injury. However, the absence of control groups precluded drawing any conclusion with respect to the impact of hydroxocobalamin on outcome \[[@CR13], [@CR14]\]. Nguyen et al. reported that the use of hydroxocobalamin was associated with fewer episodes of pneumonia while mortality was unaffected \[[@CR15]\]. However, the association between the prevention of pneumonia lies on very low level of evidence. Other factors, especially with respect to pneumonia preventive strategies, may have accounted for the observation of lower incidence of pneumonia in this before-and-after retrospective study.

In the current study, we observed an association between hydroxocobalamin and the risk of AKI and severe AKI. These results further suggest the potential nephrotoxicity of the drug. We previously showed that hydroxocobalamin induces oxaluria with a risk of oxalate nephropathy in burn patients \[[@CR4]\]. Kidney biopsies confirmed renal calcium oxalate crystal deposits. Oxaluria was also reported in healthy volunteers and animals receiving hydroxocobalamin \[[@CR16]\]. Nitric oxide chelation could represent an additional mechanism of renal toxicity of hydroxocobalamin. In the absence of cyanide, hydroxocobalamin binds to nitric oxide. Nitric oxide is a key factor of the renal microcirculatory regulation, and inhibition of the nitric oxide pathway was shown to impair renal perfusion and oxygenation and cause kidney damage \[[@CR17]--[@CR19]\].

Cyanide is a rapidly lethal mitochondrial poison. The plasma cyanide level is difficult to measure and not readily available, and none of the patients included in this study had a plasma cyanide dosage. Increased serum lactate level \> 8 mmol/L was reported to be a fair surrogate biomarker of cyanide poisoning as a biomarker of mitochondrial dysfunction \[[@CR10]\]. In our study, hydroxocobalamin had no impact in the subgroup of patients with high plasma lactate level. The lack of evidence of any association between hydroxocobalamin and survival in our study and the risk of AKI question the risk-benefit ratio in these patients. Of note, hydroxocobalamin costs about €1000/\$1200 per vial.

We acknowledge the limitations of our study. First, the retrospective nature introduced some bias. Performing a randomized control trial in this setting would be highly difficult due to the low incidence of smoke inhalation and the existing cognitive biases toward the potential protective effects of hydroxocobalamin. Second, the relative low number of patients with very high plasma lactate level precludes drawing firm conclusion in patients with a high probability of cyanide poisoning and in most severe patients. Third, we could not confirm cyanide levels in any patient, which makes it hard to determine if hydroxocobalamin could benefit patients with confirmed cyanide poisoning. Finally, rhabdomyolysis may be a confounding factor with the elevated serum creatinine. However, we did not find any correlation between admission serum creatinine, maximal serum creatinine at day 7 or during hospitalization in ICU, and the pic of creatinine phosphokinase.

Conclusion {#Sec12}
==========

In this multicenter observational study of ICU patients with smoke inhalation, administration of hydroxocobalamin was independently associated with AKI and showed no association with survival. The role of hydroxocobalamin following smoke inhalation needs further consideration and critical appraisal.
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